All In Biotech

Drug Trial Radar · NCT05620823

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 608 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

608

Actual

Start

Dec 19, 2022

Primary completion

Feb 3, 2025

Study completion Dec 23, 2025

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Nov 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week extension period.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

  • PovorcitinibDrug

    Oral; Tablet

  • PlaceboDrug

    Oral; Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR)Time frame: Week 12

Locations

104 sites in 12 countries. Site status is shown where the registry gives one.

  • Investigative Site US303

    Phoenix, Arizona

  • Investigative Site US335

    Arkansas City, Arkansas

  • Investigative Site US307

    Fort Smith, Arkansas

  • Investigative Site US315

    Laguna Niguel, California

  • Investigative Site US326

    Los Angeles, California

  • Investigative Site US323

    San Francisco, California

  • Investigative Site US306

    Boca Raton, Florida

  • Investigative Site US320

    Boca Raton, Florida

  • Investigative Site US317

    Hialeah, Florida

  • Investigative Site US338

    Margate, Florida

  • Investigative Site US321

    North Miami Beach, Florida

  • Investigative Site US316

    Orlando, Florida

  • Investigative Site US328

    Tampa, Florida

  • Investigative Site US336

    Tampa, Florida

  • Investigative Site US311

    Marietta, Georgia

  • Investigative Site US327

    Chicago, Illinois

  • Investigative Site US319

    Skokie, Illinois

  • Investigative Site US337

    Indianapolis, Indiana

  • Investigative Site US341

    Bowling Green, Kentucky

  • Investigative Site US334

    Metairie, Louisiana

  • Investigative Site US333

    Baltimore, Maryland

  • Investigative Site US325

    Columbia, Maryland

  • Investigative Site US318

    Beverly, Massachusetts

  • Investigative Site US304

    Boston, Massachusetts

  • Investigative Site US310

    Brighton, Massachusetts

  • Investigative Site US302

    St Louis, Missouri

  • Investigative Site US331

    Albuquerque, New Mexico

  • Investigative Site US324

    Kew Gardens, New York

  • Investigative Site US339

    Bexley, Ohio

  • Investigative Site US330

    Boardman, Ohio

  • Investigative Site US314

    Cincinnati, Ohio

  • Investigative Site US312

    Cleveland, Ohio

  • Investigative Site US301

    Portland, Oregon

  • Investigative Site US340

    Bellaire, Texas

  • Investigative Site US300

    Plano, Texas

  • Investigative Site US313

    Norfolk, Virginia

  • Investigative Site US308

    Spokane, Washington

  • Investigative Site AT304

    Graz, Austria

  • Investigative Site 00A

    Innsbruck, Austria

  • Investigative Site AT306

    Innsbruck, Austria

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.